Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 3/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6087316 | 1.00 | SRD5A2 (0.48) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6087109 | 0.82 | CFD (0.56) | SRD5A2LTA4H | |
| SCHEMBL6087115 | 0.82 | CFD (0.56) | SRD5A2LTA4H | |
| SCHEMBL6087646 | 0.80 | LTA4H (0.55) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6087655 | 0.80 | LTA4H (0.55) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6087478 | 0.76 | SRD5A2 (0.81) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6467439 | 0.74 | AS3MT (0.52) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6087534 | 0.74 | SRD5A2 (0.64) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6087410 | 0.70 | SRD5A2 (0.58) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL5507380 | 0.68 | SRD5A2 (0.78) | SRD5A2MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125906-B2 | Indole derivatives having anti-angiogenetic activity | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | FLT1, FLT4, VEGFA | SRD5A2 1504/4885MEN1 2145/4885NPC1 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.